Lilly's triple-acting GLP-1 drug retatrutide, expected for launch next year, produced the most powerful pharmacological pain reduction ever recorded for knee arthritis. The finding was unexpected and points to GLP-1s as potential game-changers for America's massive chronic pain burden.